OPINION Persistent hypothyroid symptoms in a patient with a normal thyroid stimulating hormone level
INTRODUCTION
As in most cases hypothyroidism is a permanent condition, affected patients rely on life-long replacement therapy. For many patients such therapy, usually provided as synthetic levothyroxine (LT4), is entirely satisfactory and fully resolves the symptoms of untreated hypothyroidism [1] . However, some patients do not feel that they are returned to full health, and note decreased quality of life, often dating from their diagnosis of hypothyroidism. Some patients may feel better while taking combination therapy consisting of both LT4 and liothyronine (LT3). However, for some other patients, combination therapy does not provide the solution. A description of such an unhappy patient is provided in Table 1 . After summarizing the data regarding patient-reported dissatisfaction, this review describes the evidence suggesting that LT4 therapy may not replicate normal physiology. The significance of circulating total triiodothyronine and free triiodothyronine (T3 and FT3) levels has been a source of contention, and this issue is discussed. This review also outlines the results of combination therapy trials that have been conducted thus far. Alternative explanations for unresolved symptoms are explored. Finally, areas where new research is needed are identified.
measures that are specific to particular diseases, such as thyroid disease. Several questionnaires specific to thyroid disorders were recently evaluated and four related to hypothyroidism and benign thyroid disease were studied [2 && ]. The highest quality instruments for assessing symptoms in patients with hypothyroidism were found, in this recent metaanalysis [2 && ], to be the Thyroid-Specific PatientReported Outcomes Measure (ThyPRO) [3, 4] and Thyroid Treatment Satisfaction Questionnaire [5, 6] . Many patients report that LT4 provides satisfactory therapy for their hypothyroidism. However, this is not universally the case. In a study from the United Kingdom, 40.3% of treated patients had symptoms of hypothyroidism, compared with 24.9% of a control population using a Thyroid Symptom Questionnaire score of greater than 4 as a measure of dissatisfaction with therapy [7] . Another study, in which participants taking LT4 were recruited by letter and then completed questionnaires assessing well being, also showed lower scores in two different questionnaires in the euthyroid patients taking LT4, although the comparison was with standard reference values, rather than a matched control group [8] . In several more recent studies, treated female patients with hypothyroidism were found to have worse quality of life compared with control groups using the RAND-36 Short Form Survey Instrument (SF-36) [ ]. One of these studies, which examined patients before and after initiation of LT4, showed improvement in some ThyPRO and SF-36 subscales as serum thyroid stimulating hormone (TSH) was normalized from a median of 8.1 to a median of 2.6 mIU/l. However, persistent deficits were noted in other subscales despite treatment. Sample patient comments regarding their therapy for hypothyroidism gathered during an online patient survey hosted on two patient advocate websites in 2016 are shown in Fig. 1 .
COMPARISON OF EUTHYROID PHYSIOLOGY WITH PHYSIOLOGY DURING LEVOTHYROXINE TREATMENT
It has been well established that individuals receiving LT4 therapy have higher serum levels of total thyroxine (T4) and free thyroxine (FT4) than endogenously euthyroid individuals, and that they therefore also have higher T4/T3 or FT4/FT3 ratios [13] [14] [15] [16] . Of the recent trials using current assay methodology for measuring T3 and FT3, the majority show that the concentrations of these analytes are lower in patients taking LT4 than in euthyroid controls [14] [15] [16] . Furthermore, these trials suggest that LT4 therapy needs to be provided at doses that lower TSH levels to achieve a FT3 in the KEY POINTS Patient-reported outcomes indicate impaired quality of life in some patients treated for hypothyroidism.
Patients receiving LT4 therapy have higher total thyroxine/total triiodothyronine ratios than euthyroid controls and may also have lower serum total triiodothyronine concentrations.
Trials of combination therapy with LT3 have failed to show clear superiority of combination therapy.
There are multiple factors that could potentially contribute to impaired quality of life in patients receiving LT4 therapy.
A large combination therapy trial with LT3 administered three times daily, targeting those who do not feel well taking LT4, and stratifying results by genotype may provide answers regarding how to optimize therapy for hypothyroidism. normal range. These trials, however, were retrospective [14] [15] [16] and/or did not use each patient as their own control [14, 16] . One trial, in which patients were studied prethyroidectomy and postthyroidectomy, showed maintenance of T3 levels, based on the average T3 levels [13] . However, eight of the 50 individual patients (16%) did have lower T3 levels when being treated with LT4 ( Fig. 2 ). There appeared to be a trend for lower T3 levels during LT4 therapy to be associated with higher TSH values when T3 was measured by tandem mass spectrometry, but not when an immunoassay was used. Although sex hormone-binding globulin, cholesterol levels, and bone markers are generally considered to be relatively insensitive measures of thyroid status compared with TSH levels, a recent study comparing these measures in patients prethyroidectomy and postthyroidectomy showed that these measures were best normalized in patients with mildly suppressed TSH values in the range of less than 0.03 to 0.3 mIU/l or less [17 && ]. If confirmed, this could suggest that TSH alone may not provide sufficient insight into thyroid status.
SIGNIFICANCE OF CIRCULATING TRIIODOTHYRONINE CONCENTRATIONS
The concept of LT4 as a prohormone, with each tissue being able to convert FT4 to FT3 as needed, is physiologically appealing. If thyroid hormone is supplied as LT3 monotherapy this may be nonphysiologic, as it is possible that individual tissues and cells might be forced to accept a specific amount of FT3, regardless of their individual needs. There has been recent debate as to whether the T3 levels achieved during treatment of hypothyroidism are important [18] . Traditionally thyroid status in patients being treated for hypothyroidism with LT4 has been monitored using serum TSH, and potentially also FT4, concentrations [1] . The 'choosing wisely' initiative of the American Board of Internal Medicine Foundation, supported by several endocrine societies, recommends against considering T3 levels when adjusting LT4 therapy [19] . However, the hypothesis that subnormal T3 levels are both prevalent and important has fueled the 14 or so trials of combination therapy with both LT4 and LT3 that have been conducted thus far.
All trials of combination therapy have used LT3 given as either a once or twice daily dose. An animal study, suggesting that such periodic delivery may also be nonphysiologic, was recently conducted [20] . Rodents were treated with either continuous LT4 alone, or continuous LT4 and periodic LT3 injections, or continuous delivery of both T4 and T3 via subcutaneously implanted pellets. In this study, the T4 and T3 levels seen in euthyroid control animals was only recapitulated by subcutaneous pellets which continuously supplied T4 and T3. The authors suggested that during T4 monotherapy, the hypothalamus exhibits less inactivation of the type 2 deiodinase than other tissues and therefore, produces T3 more efficiently than other tissues [20] . Thus, it was hypothesized, that TSH secretion is normalized before T3 levels are fully normalized in other tissues, resulting in low T3 levels in many peripheral tissues. Furthermore, markers of euthyroidism, such as mitochondrial and a-glycerolphosphate dehydrogenase content of liver and muscle and serum cholesterol levels, better approximated values in control animals when sustained delivery of both T4 and T3 was employed [20] .
A recent cross-sectional study using data from the 2001-2012 National Health and Nutrition Examination Survey compared biochemical data and clinical data from healthy euthyroid participants to euthyroid LT4-treated participants [21 & ]. The LT4-treated group had lower serum T3 and FT3 concentrations. They were also more frequently treated with statins and antidepressants and had a higher BMI. However, in multivariate analysis there was no association between serum T3 concentrations and any of the clinical parameters assessed, except for age and sex. These data suggest that although serum T3 levels are lower in LT4-treated patients than in euthyroid controls, the physical and psychologic morbidity associated with receiving LT4 treatment for hypothyroidism may not be 
SUMMARY OF COMBINATION THERAPY TRIALS
Stimulated by the knowledge that the native thyroid gland directly produces T3, and the finding that some individuals being treated for hypothyroidism may have low T3 levels, 14 trials, comparing combination therapy with LT4 and LT3 to monotherapy with LT4, have been conducted [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (reviewed in [1] ). Despite this extensive body of evidence, clear benefit from combination therapy has not yet been shown. These trials have not shown improvement in a variety of outcome measures with the use of combination therapy. For example, thyroid-related symptoms were not different between treatment groups, and body weight was not lower during combination therapy, except in one study [22] using a combination therapy dose that suppressed serum TSH. Health-related quality of life or mood was not improved in the majority of trials, although two trials showed improvement in a few measures [31, 34] , and two trials showed improvement in a majority of measures [24, 29] . Similarly, with neurocognitive function, most trials showed no improvement, one trial showed improvement in a few measures [26] , and one trial showed improvement in several measures [24] . A preference for synthetic combination therapy was seen in four out of the five crossover trials in which preference was assessed [23, 24, 26, 29] . Patients preferred combination therapy in one of the trials with a parallel design [22] . However, the largest trial, which had a parallel design, was not associated with patient preference for combination therapy [31] .
However, there are some limitations to these trials [1] . Most of these trials had fewer than 100 patients. The length of the trials has been short, with most being 5-16 weeks in duration. Only four of the trials were 4-12 months long. Another concern with these trials is the frequency of LT3 dosing. When LT3 is given once daily, steady serum levels of T3 are not maintained [36 & ], although they are maintained with three times a day dosing [37] . There were nine trials that used once daily LT3 dosing [23, 24, [26] [27] [28] [29] [30] [31] 33] , four trials that employed twice daily LT3 dosing [22, 25, 32, 34] , and none that used LT3 given three times daily. Some studies resulted in different TSH concentrations between groups, potentially confounding the study results, or reducing the ability to demonstrate differences between the groups. The predominance of healthy middleaged females in the current studies leads to potential problems with generalizing results to the entire hypothyroid population, including the elderly, males, and those with comorbidities. The heterogeneity of the trials makes it difficult to assess outcomes with the use of meta-analyses [38] [39] [40] .
The type 2 deiodinase enzyme is responsible for converting T4 to T3 in the thyroid gland, brain, pituitary, skeletal muscle, and heart [1] . There has been interest in potential consequences of polymorphisms in the type 2 deiodinase gene, including the Thr92Ala polymorphism [1] . This polymorphism may possibly affect enzymatic function [41] and be associated with genes involved in determining oxidative stress in brain tissue [42] . Approximately 10-16% of the population are homozygous for this substitution. A secondary analysis of the largest combination therapy trial suggested that patients with a particular genetic variation, the Thr92Ala variant of the type 2 deiodinase, responded differently to combination therapy [43] . Not only did these individuals have worse scores on the general health questionnaire while taking LT4, but they also had a better response to combination therapy in which 50-mg LT4 was replaced by 10-mg LT3. As this study was retrospective in nature and the authors did not have a sufficient sample size to correct for multiple comparisons, a well powered prospective study is still awaited. A recent study of quality of life in the general population and in individuals being treated for hypothyroidism examined the association of this polymorphism with impaired quality of life [9 && ]. No association was found in either population, although the study may have been underpowered. It is possible that if patients with this particular variant are specifically targeted in future combination therapy trials, a greater benefit of combination therapy might be documented.
POSSIBLE EXPLANATION FOR UNRESOLVED SYMPTOMS
A recent study has shown that although quality of life does improve after patients with hypothyroidism are rendered euthyroid with LT4, these individuals still have residual impairment in health-related quality of life as assessed using the ThyPRO and SF-36 questionnaires, using normative data as the comparator [10 && ]. There are many factors that contribute to health-related quality of life. These include physical factors, psychological factors, social factors, economic factors, disease symptoms, cultural set-up, activities of daily role, and treatment [44] . The decreased quality of life in biochemically euthyroid patients with hypothyroidism could have several potential causes from among these factors, with treatment for their disease perhaps not being the only relevant factor. For example, with respect to physical factors, impaired quality of life has been found to be associated with increased BMI in patients being treated for hypothyroidism [11] , suggesting the importance of considering BMI as a possible contributant to quality of life. Certainly, preference for combination therapy has been associated with weight loss achieved during therapy in both a trial of synthetic combination therapy [22] and in a trial of desiccated thyroid extract [45] .
Alternatively, there may be an ascertainment bias because patients who do not feel well are more likely to be screened for and diagnosed with hypothyroidism ( Table 2 ). For example, in one study individuals with psychological stress were more likely to be referred for screening for hypothyroidism but were no more likely to actually have hypothyroidism than the general population [46] . Being categorized as having a chronic condition could also prove detrimental to a patient's well being. Some support for this particular explanation is provided by a study, showing that being aware of diagnoses such as diabetes, hypertension, and hypothyroidism were linked with worse self-reported health [47] . Many patients with hypothyroidism may also have other chronic conditions, and there may be overlap in the symptoms associated with these conditions. For example, rheumatologic disorders may be associated with similar symptoms such as fatigue, waking up unrefreshed, and trouble thinking or remembering [48] , and some tools designed to detect systemic autoimmune rheumatologic disease may have moderate validity for detecting thyroid disease also [49] . Some studies also suggest that individuals with hypothyroidism are more likely to be diagnosed with disorders such as anxiety and depression [50] .
On the other hand, it is possible that there is some aspect of the hypothyroid state, which is difficult to measure or capture in survey instruments, that is not adequately reversed with LT4 monotherapy. It is also possible that Hashimoto's hypothyroidism may cause morbidity that is specifically related to the underlying autoimmunity, rather than the thyroid status [51, 52] . Finally, variations in genes associated with thyroid hormone metabolism and action could be associated with an inferior response to LT4 [43] , or could be associated with other conditions that affect quality of life [42] .
POTENTIAL DIRECTIONS FOR FUTURE RESEARCH
With regard to future research into why some patients with hypothyroidism continue to have unresolved symptoms, there is still a possibility that future trials of combination therapy will provide answers. Future trials may need to study larger numbers of patients, while also ensuring serum TSH values are not different in the treatment groups, and employing standardized outcomes and validated measures of quality of life. Larger sample sizes would not only allow for more power to detect differences between groups, but would also allow detection of differences in analyses stratified by baseline symptoms. In addition, future trials may benefit from focusing on particular subgroups of patients, such as those who do not feel well, those with type 2 deiodinase polymorphisms or other genetic variations, athyreotic patients, or those have particularly low serum T3 levels during monotherapy. The population studied should also include those with other medical conditions to ensure that those studied are representative of the general population with hypothyroidism. Other considerations in future trials would be using more frequent administration of LT3 to achieve more stable serum T3 concentrations. Three times daily LT3 therapy (as monotherapy) has been successfully achieved [37] , but such frequent medication administration is challenging to maintain during long-term therapy. A sustained release T3 preparation would clearly circumvent this issue.
CONCLUSION
Levothyroxine is easy to administer and monitor, and results in excellent quality of life for most patients. Thus, clinicians have the opportunity to prescribe an excellent therapy that rapidly and effectively reverses the stigmata of hypothyroidism. This is indeed a significant advance since hypothyroidism was treated by grafting half a sheep's thyroid gland into a myxedematous patient [53] . However, despite the successes in treating hypothyroidism, there are clearly aspects of treating hypothyroidism that are not yet understood (Fig. 3 ). There is a need to fine-tune thyroid hormone replacement so that it provides satisfactory treatment to all those affected by hypothyroidism. Development of a sustained release T3 preparation and harnessing thyroid follicles generated from stem cells are potential avenues through which this might be achieved.
